![]() |
Name |
Talaketides C
|
Molecular Formula | C15H24O5 | |
IUPAC Name* |
(4,6-dimethoxy-1,3-dimethyl-2-oxocyclohex-3-en-1-yl)2-methylbutanoate
|
|
SMILES |
CCC(C)C(=O)OC1(C)C(=O)C(C)=C(OC)CC1OC
|
|
InChI |
InChI=1S/C15H24O5/c1-7-9(2)14(17)20-15(4)12(19-6)8-11(18-5)10(3)13(15)16/h9,12H,7-8H2,1-6H3/t9-,12+,15+/m0/s1
|
|
InChIKey |
RCKOGKAEFJRERK-TURKWSHLSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 284.35 | ALogp: | 2.2 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 61.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 20 | QED Weighted: | 0.726 |
Caco-2 Permeability: | -4.605 | MDCK Permeability: | 0.00002160 |
Pgp-inhibitor: | 0.993 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.887 |
30% Bioavailability (F30%): | 0.97 |
Blood-Brain-Barrier Penetration (BBB): | 0.969 | Plasma Protein Binding (PPB): | 56.85% |
Volume Distribution (VD): | 0.753 | Fu: | 52.57% |
CYP1A2-inhibitor: | 0.027 | CYP1A2-substrate: | 0.421 |
CYP2C19-inhibitor: | 0.057 | CYP2C19-substrate: | 0.885 |
CYP2C9-inhibitor: | 0.011 | CYP2C9-substrate: | 0.044 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.126 |
CYP3A4-inhibitor: | 0.245 | CYP3A4-substrate: | 0.667 |
Clearance (CL): | 9.97 | Half-life (T1/2): | 0.332 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.639 |
Drug-inuced Liver Injury (DILI): | 0.427 | AMES Toxicity: | 0.036 |
Rat Oral Acute Toxicity: | 0.072 | Maximum Recommended Daily Dose: | 0.027 |
Skin Sensitization: | 0.416 | Carcinogencity: | 0.047 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.026 |
Respiratory Toxicity: | 0.116 |